Shanghai Escugen Biotechnology Co., Ltd
Clinical trials sponsored by Shanghai Escugen Biotechnology Co., Ltd, explained in plain language.
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called ESG401 in people with advanced solid tumors that had spread or couldn't be removed by surgery. The main goals were to find a safe dose and see if the drug could shrink tumors in cancers like breast, lung, colorectal, and ovarian. The trial invo…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New antibody tested for Tough-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a new antibody drug called ESG206 in adults with advanced B-cell cancers that had stopped responding to standard treatments. The main goal was to find a safe dose by giving small groups of patients increasing amounts of the drug and closely monitorin…
Phase: PHASE1 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC